BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:53 PM
 | 
Aug 28, 2008
 |  BC Extra  |  Clinical News

Cyclacel gives seliciclib update

Cyclacel (NASDAQ:CYCC) said seliciclib would "probably not" demonstrate an improvement in progression-free survival, the primary endpoint, in the Phase IIb APPRAISE trial to treat non-small cell lung cancer (NSCLC). The company said the trial's independent data review committee (IDRC)...

Read the full 177 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >